Cyclic nucleotide phosphodiesterases in pancreatic islets

Diabetologia

Volumn 46, Issue 9, 2003, Pages 1179-1189

  Pyne, N J ^a   Furman, B L ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Cyclic AMP; Cyclic GMP; Insulin secretion; Islet beta cell; Phosphodiesterase

Indexed keywords

4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; 6 (5,6 DIMETHOXYBENZO[B]THIEN 2 YL) 4,5 DIHYDRO 5 METHYL 3(2H) PYRIDAZINONE; AROFYLLINE; ATIZORAM; CILOMILAST; CILOSTAMIDE; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; DIPYRIDAMOLE; ENOXIMONE; GLUCOSE; INSULIN; MILRINONE; N CYCLOHEXYL 4 (1,2 DIHYDRO 2 OXO 6 QUINOLYLOXY) N (2 HYDROXYETHYL)BUTYRAMIDE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PICLAMILAST; RECEPTOR BLOCKING AGENT; ROLIPRAM; SCH 51866; SIGUAZODAN; SILDENAFIL; VINPOCETINE; ZAPRINAST; ZARDAVERINE;

5' UNTRANSLATED REGION; ADIPOCYTE; ADIPOSE TISSUE; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; DIABETES MELLITUS; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HUMAN; IN VIVO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; LIVER; LIVER CELL; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; CYCLIC AMP; CYCLIC GMP; HUMANS; ISLETS OF LANGERHANS; ISOENZYMES;

EID: 0141594650     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-003-1176-7     Document Type: Review

References (98)

1. Perry MJ, Higgs GA (1998) Chemotherapeutic potential of phosphodiesterase inhibitors. Curr Opin Chem Biol 2:472-481
2. Mehats C, Andersen CB, Filopanti M (2002) Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends. Endocrinol Metab 13:29-35
3. Soderling SH, Beavo JA (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12:174-179
4. Han P, Werber J, Surana Met al. (1999) The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion. J Biol Chem 274: 22337-22344
5. Clapham JC, Widerspin AF (2001) Cloning of dog heart PDE1A - a first detailed characterization at the molecular level. Gene 268:165-171
6. Yan C, Zhao AZ, Bentley JK et al. (1995) Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons. Proc Nat Acad Sci USA 92:9677-9681
7. Pyne NJ, Cooper ME, Houslay MD (1986) Identification and characterization of both the cytosolic and particulate forms of cyclic GMP-stimulated cyclic AMP phosphodiesterase from rat liver. Biochem J 234:325-334
8. Pyne NJ, Cooper ME, Houslay MD (1987) The insulin-and glucagon-stimulated 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase from rat liver. Purification, characterization and inhibitor sensitivity. Biochem J 242: 33-42
9. Harrison SA, Reifsnyder DH, Gallis B et al. (1986) Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol Pharmacol 29:506-514
10. Torphy TJ (1998) Phosphodiesterase isozymes. Molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157:351-370
11. Houslay MD (1998) Adaptation in cyclic AMP signalling processes: a central role for cyclic AMP phosphodiesterases. Semin Cell Dev Biol 9:161-167
12. Corbin JD, Francis SH (1999) Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 274:13729-13732
13. Pittler SJ, Baehr W, Wasmuth JJ et al. (1990) Molecular characterization of human and bovine rod photoreceptor cGMP phosphodiesterase alpha-subunit and chromosomal localization of the human gene. Genomics 6:272-283
14. Michaeli T, Bloom TJ, Martins T et al. (1993) Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase- deficient Saccharomyces cerevisiae. J Biol Chem 268:12925-12932
15. Fisher DA, Smith JF, Pillar JS et al. (1998) Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 273:15559-15564
16. Fujishigi K, Kotera J, Michibata H et al. (1999) Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 274:18438-18445
17. Fawcett L, Baxendale R, Stacey P et al. (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 97:3702-3707
18. Lester LB, Langenberg LK, Scott JD (1997) Anchoring of protein kinase A facilitates hormone-mediated insulin secretion. Proc Natl Acad Sci USA 94:14942-14947
19. Persaud SJ, Jones PM, Howell (1990) Glucose-stimulated insulin secretion is not dependent on activation of protein kinase A. Biochem Biophys Res Commun 173:833-839
20. Grill V, Cerasi E (1973) Activation by glucose of adenyl cyclase in pancreatic islets of the rat. FEBS Lett 33: 311-314
21. Sharp GW (1979) The adenylate cyclase-cyclic AMP system in islets of Langerhans and its role in the control of insulin release. Diabetologia 16:287-296
22. Holz GG, Habener JF (1992) Signal transduction crosstalk in the endocrine system:pancreatic beta-cells and the glucose competence concept. Trends Biochem Sci 17 388-393
23. Harndähl L, Jing XJ, Ivarsson R et al. (2002) Important role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of insulin. J Biol Chem 277:37446-37455
24. 2+ channels in rat islet beta-cells. Pflugers Arch 435:578-580
25. 2+ release in INS-1 pancreatic beta-cells. J Physiol 536:375-385
26. Islam Md S, Leibiger I, Leibiger Bet al. (1998) In situ activation of the type 2 ryanodine receptor in pancreatic beta cells requires cAMP-dependent phosphorylation. Proc Natl Acad Sci USA 95:6145-6150
27. 2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-(7-37). J Biol Chem 274:14147-14156
28. Yaney GC, Civelek VN, Richard AM et al. (2001) Glucagon-like peptide 1 stimulates lipolysis in clonal pancreatic beta-cells (HIT). Diabetes 50:56-62
29. Renstrom E, Eliasson L, Rorsman P (1997) Protein kinase A-dependent and independent stimulation of exocytosis by cAMP in mouse pancreatic B-cells. J Physiol 502:105-118
30. Kashima Y, Miki T, Shibasaki T et al. (2001) Critical role of cAMP-GEFII-Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 276:46046-46053
31. Drucker DJ, Philippe J, Mojsov Set al. (1987) Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84:3434-3438
32. Elrick LJ, Docherty K (2001) Phosphorylation-dependent nucleocytoplasmic shuttling of pancreatic duodenal homeobox-1. Diabetes 500:2244-2252
33. Wang X, Zhou J, Doyale ME et al. (2001) Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 142: 1820-1827
34. Ding WQ, Dong M, Ninova D et al. (2003) Forskolin suppresses insulin gene transcription in islet beta-cells through a protein kinase A-independent pathway. Cell Signal 15:27-35
35. Jonas JC, Laybutt DR, Steil GM et al. (2001) High glucose stimulates early response gene c-Myc expression in rat pancreatic beta cells. J Biol Chem 276:35375-35381
36. Susimi S, Roche E, Prentki M et al. (1998) Glucose and glucoincretin peptides synergize to induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic beta(INS-1) cells. FASEB J 12:1173-1182
37. Calleja V, Ruiz Enriquez P, Filloux C et al. (1997) The effect of cyclic adenosine monophosphate on the mitogen-activated protein kinase pathway depends on both the cell type and the type of tyrosine kinase-receptor. Endocrinology 138:1111-1120
38. Benes C, Roisin MP, Van Tan H et al. (1998) Rapid activation and nuclear translocation of mitogen-activated protein kinases in response to physiological concentration of glucose in the MIN6 pancreatic beta cell line. J Biol Chem 273:15507-15513
39. Benes C, Poitout V, Marie J-C et al. (1999) Mode of regulation of the extracellular signal-regulated kinases in the pancreatic β-cell line MIN6 and their implication in the regulation of insulin gene transcription. Biochem J 340:219-225
40. Ehses JA, Pelech SL, Pederson RA et al. (2002) Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J Biol Chem 277:37088-37097
41. Andersen HU, Mauricio D, Karlsen AE et al. (1996) Interleukin-1 beta-induced nitric oxide production from rat isolated islets is modulated by D-glucose and 3-isobutyl-1-methyl xanthine. Eur J Endocrinol 134:251-259
42. Loweth AC, Williams GT, Scarpello JH et al. (1996) Heterotrimeric G-proteins are implicated in the regulation of apoptosis in pancreatic beta-cells. Exp Cell Res 229:69-76
43. Ahmad M, Flatt PR, Furman BL et al. (2000) The role of cyclic GMP-inhibited cyclic AMP-specific phosphodiesterase (PDE3) in regulating clonal BRIN-BD11 insulin secreting cell survival. Cell Signal 12:541-548
44. Vara E, Tamarit-Rodriguez J (1991) Does cyclic guanosine monophosphate mediate noradrenaline-induced inhibition of islet insulin secretion stimulated by glucose and palmitate? Biochem J 278:243-248
45. Green IC, Delaney CA, Cunningham JM et al. (1993) Interleukin-1 beta effects on cyclic GMP and cyclic AMP in culture rat islets of Langerhans-arginine-dependence and relationship to insulin secretion. Diabetologia 36:9-16
46. Verspohl EJ, Ammon HP (1989) Atrial natriuretic peptide (ANP) acts via specific binding sites on cGMP system of rat pancreatic islets without affecting insulin release. Naunyn Schmiedebergs Arch Pharmacol 339:348-353
47. Jones PM, Persaud SJ, Bjaaland T et al. (1992) Nitric oxide is not involved in the initiation of insulin secretion from rat islets of Langerhans. Diabetologia 35:1020-1027
48. 2+ concentration in rat pancreatic beta-cells. Life Sci 65:1515-1522
49. Smukler SR, Tang L, Wheeler MB et al. (2002) Exogenous nitric oxide and endogenous glucose-stimulated beta-cell nitric oxide augment insulin release. Diabetes 51:3450-3460
50. 2+ concentration and insulin secretion in rat pancreatic (beta)-cells. Am J Physiol Cell Physiol 284:C1215-C1222
51. Ropero AB, Fuentes, E, Rovira JM et al. (1999) Non-genomic actions of 17β-oestradiol in mouse pancreatic β-cells are mediated by a cGMP-dependent protein kinase. J Physiol 521:397-407
52. Loweth AC, Williams GT, Scarpello JH (1997) Evidence for the involvement of cGMP and protein kinase G in nitric oxide-induced apoptosis in the pancreatic B-cell line, HIT-T15. FEBS Lett 400:285-288
53. 2+, calmodulin and trifluoperazine. Biochem J 197:459-464
54. Capito K, Hedeskov CJ, Thams P (1986) Cyclic AMP phosphodiesterase activity in mouse pancreatic islets. Effects of calmodulin and phospholipids. Acta Endocrinol 111:533-538
55. Lipson LG, Oldham SB (1983) The role of calmodulin in insulin secretion: the presence of a calmodulin-stimulatable phosphodiesterase in pancreatic islets of normal and pregnant rats. Life Sci 32:775-780
56. Ahmad M, Abdel-Wahab YHA, Tate R et al. (2000) Effect of type-selective inhibitors on cyclic nucleotide phosphodiesterase activity and insulin secretion in the clonal insulin secreting cell line BRIN-BD11. Br J Pharmacol 129:1228-1234
57. Shafiee-Nick R, Pyne NJ, Furman BL (1995) Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity. Br J Pharmacol 115:1486-1492
58. Furman BL, Pyne NJ (1990) Islet phosphodiesterase isoenzymes and insulin secretion. Diabet Med 7:19A
59. Zhao AZ, Zhao H, Teague J et al. (1997). Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proc Natl Acad Sci USA 94:3223-3228
60. Thompson WJ (1991) Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol Ther 51:13-33
61. Shahid M, van Amsterdam RG, Boer J de et al. (1991) The presence of five cyclic nucleotide phosphodiesterase isoenzyme activities in bovine tracheal smooth muscle and the functional effect of selective inhibitors. Br J Pharmacol 104:471-477
62. Shafiee-Nick R, James RFL, London NJM et al. (1994) Cyclic 3′5′ AMP phosphodiesterases in human islets. Diabet Med 11 (Suppl 1):S31
63. Parker JC, Van Volkenberg MA, Ketchum RJ et al. (1995) Cyclic AMP phosphodiesterases of human and rat islets of Langerhans: contributions of types III and IV to the modulation of insulin secretion. Biochem Biophys Res Commun 217:916-923
64. Liu H, Maurice DH (1998) Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 125:1501-1510
65. Islam MS (2002) The ryanodine receptor calcium channel of β-cells: molecular regulation and physiological significance. Diabetes 51:1299-1309
66. Kenakin TP, Beek D (1987) Measuement of antagonist affinity for purine receptors of drugs producing concomitant phosphodiesterase blockade; the use of pharmacological resultant analysis. J Pharmacol Exp Ther 243:482-486
67. 2+ sensitivity in β-cells. Endocrinology 139: 1133-1140
68. Jin SL, Bushnik T, Lan L, Conti M (1998) Subcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene. J Biol Chem 273:19672-19678
69. Degerman E, Belfrage P, Manganiello VC (1996) cGMP-inhibited phosphodiesterases (PDE3 gene family). Biochem Soc Trans 24:1010-1014
70. Shakur Y, Takeda K, Kenan Y et al. (2000) Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum. J Biol Chem 275:38749-38761
71. Degerman E, Belfrage P, Manganiello VC (1997) Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem 272:6823-6826
72. Movsesian MA (2002) PDE3 cyclic nucleotide phosphodiesterases and the compartmentation of cyclic nucleotide-mediated signaling in cardiac myocytes. Basic Res Cardiol 97 (Suppl 1):183-190
73. Cruickshank SF, Drummond RM, Furman BL (2002) Inhibition of islet phosphodiesterase PDE3 increases the calcium response to glucose. Br J Pharmacol 135:228P
74. Kurtz A, Gotz KH, Hamann M et al. (1998) Stimulation of renin secretion by nitric oxide is mediated by phosphodiesterase 3. Proc Natl Acad Sci USA 95:4743-4747
75. Sette C, Iona S and Conti M (1994) The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J Biol Chem 269:9245-9252
76. Murthy KS, Zhou H, Makhlouf GM (2002) PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle. Am J Physiol Cell Physiol 282:C508-C517
77. Persaud SJ, Asare-Anane H, Jones PM (2002) Insulin receptor activation inhibits insulin secretion from human islets of Langerhans. FEBS Lett 510:225-228
78. Koranyi L, James DE, Kraegen EW et al. (1992) Feedback inhibition of insulin gene expression by insulin. J Clin Invest 89:432-436
79. Marchetti P, Scharp DW, McLear M (1995) Insulin inhibits its own secretion from isolated, perifused human pancreatic islets. Acta Diabetol 32:75-77
80. Zawalich WS, Tesz GJ, Zawalich KC (2002) Inhibitors of phosphatidylinositol 3-kinase amplify insulin release from islets of lean but not obese mice. J Endocrinol 174:247-258
81. Zhao AZ, Bornfeldt KE, Beavo JA (1998) Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Invest 102:869-873
82. Cases JA, Gabriely I, Ma XH et al. (2001) Physiological increase in plasma leptin markedly inhibits insulin secretion in vivo. Diabetes 50:348-352
83. 2+ channels. J Gen Physiol 110:217-228
84. Drucker DJ, Campos R, Reynolds R et al. (1991) The rat glucagon gene is regulated by a protein kinase A-dependent pathway in pancreatic islet cells. Endocrinology 128:394-400
85. Stobie-Hayes KM, Brubacker PL (1996) Inhibition of protein kinase A-induced glucagon synthesis and secretion by glucose. Metabolism 45:347-350
86. Kahn SE (2003) The relative contribution of insulin resistance and beta cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46:3-19
87. Juhl CB, Hollingdal M, Sturis J et al. (2002) Bedtime administration of NN221, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glucose in type 2 diabetes. Diabetes 51:424-429
88. Rachman J, Barrow BA, Levy JC et al. (1997) Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40:205-211
89. Reinhardt RR, Chin E, Zhou J et al. (1995) Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J Clin Invest 95:1528-1538
90. El-Metwally M, Shafiee-Nick R, Pyne NJ et al. (1997) The effect of selective phosphodiesterase inhibitors on plasma insulin concentrations and insulin secretion in vitro in the rat. Eur J Pharmacol 324:227-232
91. Parker JC, VanVolkenburg MA, Nardone NA (1997) Modulation of insulin secretion and glycemia by selective inhibition of cyclic AMP phosphodiesterase III. Biochem Biophys Res Commun 236:665-669
92. Graham TE, Sathasivam P, Rowland et al. (2001) Caffeine ingestion elevates plasma insulin response in humans during an oral glucose tolerance test. Can J Physiol Pharmacol 79:559-565
93. Packer M, Carver JR, Rodeheffer RJ et al. (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325:1468-1475
94. Bastard JP, Pieroni L, Hainque B (2000) Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 16:192-201
95. Liang L, Beshay E, Prud'homme GJ (1998) The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. Diabetes 47:570-575
96. Besay E, Prud'homme GJ (2001) Inhibitors of phosphodiesterase isoforms III or IV suppress islet-cell nitric oxide production. Lab Invest 81:1109-1117
97. Leibowitz MD, Biswas C, Brady EJ et al. (1995). A novel insulin secretagogue is a phosphodiesterase inhibitor. Diabetes 44:66-74
98. Murray F, MacLean MR, Pyne NJ (2002) Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 137:1187-1194